eli lilly glp-1 advantage decreasing A Big Week for Drugs - by Eric Topol FDA approves new weight-loss pill,

Clinical Evidence for Semaglutide-Naltrexone Combination The strongest evidence for semaglutide plus naltrexone comes from the IMCOSI phase 2b trial (2021), which enrolled 338 patients and found that the combination resulted in approximately 20% body weight loss over 48 weeks, compared to 16% for semaglutide alonea difference that was statistically significant but modest in absolute terms

Balette says can easily get lost in the broader cultural conversation about these drugs

a Nutritional recommendations and counseling are important to support weight reduction, prevent and mitigate gastrointestinal side effects, reduce muscle and bone loss, and support long-term weight maintenance

GLP-1RA can inhibit the progression of atherosclerosis in the early phase by regulation of immune cell phenotypes

The skin is a less efficient delivery route than subcutaneous fat